Microscopic colitis is one of the most commonly missed causes of chronic diarrhea. It accounts for 10-15% of cases investigated by colonoscopy, yet it is routinely overlooked because the colon looks completely normal during the procedure. The inflammation is only visible under a microscope, which means that unless a gastroenterologist takes biopsies from normal-appearing tissue, the diagnosis will not be made. For many patients, this results in years spent under an IBS-D label when the actual problem is a specific, treatable inflammatory condition with a well-established treatment protocol.
What is microscopic colitis?
Microscopic colitis is a chronic inflammatory condition of the colon. Unlike ulcerative colitis or Crohn's disease, it does not cause visible ulceration, redness, or structural damage that can be seen with the naked eye during colonoscopy. The inflammation exists at the cellular level and is only detected when tissue samples are examined histologically. There are two recognized subtypes. Collagenous colitis is characterized by a thickened subepithelial collagen band (greater than 10 micrometers) in the colonic mucosa. Lymphocytic colitis is defined by an increased number of intraepithelial lymphocytes (greater than 20 per 100 surface epithelial cells) without significant collagen thickening. Both subtypes produce similar symptoms, primarily chronic watery diarrhea without blood.
The incidence of microscopic colitis has increased significantly over the past two decades, partly due to greater awareness and biopsy rates. Current estimates place the incidence at approximately 10-12 per 100,000 person-years in Western populations. The condition is most common in women over 50, with a female-to-male ratio of roughly 3:1, though it occurs in younger adults and men as well.
What is IBS-D?
Irritable bowel syndrome with diarrhea predominance (IBS-D) is a functional gastrointestinal disorder diagnosed using the Rome IV criteria. To qualify, a patient must have recurrent abdominal pain at least one day per week for three months, associated with defecation, a change in stool frequency, or a change in stool form, with diarrhea being the dominant pattern. IBS-D is a diagnosis of exclusion. There is no blood test, imaging study, or biopsy that confirms it. It is the label assigned when symptoms match the criteria and other conditions have been ruled out. The critical question is which conditions were actually ruled out during the workup.
How do IBS-D and microscopic colitis symptoms overlap?
The symptom overlap between IBS-D and microscopic colitis is substantial, which is why misdiagnosis occurs so frequently. Both conditions produce chronic diarrhea, abdominal cramping and discomfort, urgency, frequent bowel movements, and fatigue. In both conditions, stool is typically non-bloody, which removes one of the clinical flags that might prompt more aggressive investigation. A clinician relying solely on symptom history cannot reliably distinguish between the two.
| Feature | IBS-D | Microscopic Colitis |
|---|---|---|
| Primary symptom | Diarrhea with abdominal pain | Chronic watery diarrhea |
| Blood in stool | No | No (rarely, minimal) |
| Nocturnal diarrhea | Uncommon | More common |
| Weight loss | Uncommon | Can occur in severe cases |
| Colonoscopy appearance | Normal | Normal |
| Biopsy findings | Normal | Abnormal (collagen band or lymphocyte infiltration) |
| Inflammatory markers | Normal | May be mildly elevated |
| Response to budesonide | Minimal or none | 80%+ remission rate |
What are the key differentiators?
Several clinical features, while not definitive individually, tilt the probability toward microscopic colitis rather than IBS-D when present together.
- Watery diarrhea as the dominant symptom. Microscopic colitis typically produces high-volume watery stools, sometimes exceeding 1 liter per day in severe cases. IBS-D diarrhea is usually lower volume and more often accompanied by cramping as the primary complaint.
- Nocturnal diarrhea. Waking from sleep to have a bowel movement is uncommon in IBS-D but occurs more frequently in microscopic colitis. Nocturnal symptoms suggest an organic rather than functional cause.
- Age and sex. Women over 50 with new-onset chronic diarrhea have a meaningfully higher probability of microscopic colitis than younger patients. The median age at diagnosis is approximately 65 years.
- Medication exposure. Current or recent use of PPIs, NSAIDs, SSRIs, or certain checkpoint inhibitor immunotherapies is associated with microscopic colitis onset. Drug-induced microscopic colitis is a recognized entity.
- Lack of pain predominance. In IBS-D, abdominal pain related to defecation is a defining feature (required by Rome IV). Many microscopic colitis patients report diarrhea and urgency as their dominant complaints, with pain being secondary or absent.
- Absence of constipation alternation. IBS patients often report alternating diarrhea and constipation periods. Microscopic colitis is typically persistent diarrhea without constipation phases.
Collagenous vs lymphocytic colitis: does the subtype matter?
Both subtypes produce similar symptoms and respond to similar treatments. The distinction is histological. In collagenous colitis, the subepithelial collagen band thickens beyond the normal 3-5 micrometers to greater than 10 micrometers, sometimes reaching 30-100 micrometers. In lymphocytic colitis, the intraepithelial lymphocyte count exceeds 20 per 100 surface epithelial cells without significant collagen changes. Some researchers consider these subtypes as manifestations of a single disease spectrum rather than distinct entities. From a practical standpoint, the subtype does not change the initial treatment approach. Budesonide is first-line for both. Collagenous colitis may have a slightly higher relapse rate after budesonide discontinuation, but this is not consistent across all studies.
How are IBS-D and microscopic colitis diagnosed differently?
IBS-D is diagnosed clinically using Rome IV symptom criteria after excluding red-flag conditions through basic bloodwork and, in some cases, colonoscopy. No biopsy is required and none is typically performed if the mucosa looks normal. Microscopic colitis can only be diagnosed by histological examination of colonic biopsies. The critical step is that biopsies must be taken from normal-appearing mucosa during colonoscopy. Without this step, the diagnosis is impossible. Standard recommendations call for biopsies from multiple sites in the colon, both the right (ascending) and left (descending/sigmoid) sides, because the histological changes can be patchy.
âšī¸A colonoscopy without biopsies cannot rule out microscopic colitis. If your colonoscopy report says 'normal mucosa, no biopsies taken,' microscopic colitis has not been evaluated. This is the single most important point for patients with chronic diarrhea to understand.
How do treatment approaches differ?
IBS-D treatment is symptom-based. Standard options include dietary modification (low-FODMAP diet), loperamide for diarrhea control, antispasmodics, bile acid sequestrants (cholestyramine), and sometimes low-dose tricyclic antidepressants for pain modulation and gut transit slowing. None of these target a specific underlying mechanism because IBS-D has no identified single cause.
Microscopic colitis treatment is targeted. Budesonide, an oral corticosteroid with high topical activity and low systemic bioavailability, is the first-line treatment. The standard induction dose is 9 mg daily for 6-8 weeks, followed by a taper. Clinical remission occurs in more than 80% of patients during induction. However, relapse after discontinuation is common (60-80% within 6 months), and many patients require low-dose maintenance therapy (3-6 mg daily). For patients who do not respond to budesonide, bismuth subsalicylate and cholestyramine are second-line options. Immunomodulators (azathioprine, methotrexate) and biologics (anti-TNF agents) are reserved for refractory cases. A medication review is also essential. If a drug-induced cause is identified (PPIs, NSAIDs, SSRIs), discontinuing or substituting the offending medication may resolve the colitis entirely.
Why does budesonide response matter diagnostically?
The response to budesonide has diagnostic value beyond its therapeutic role. Because budesonide works by suppressing the specific mucosal inflammation present in microscopic colitis, a rapid and substantial improvement in diarrhea within 2-4 weeks of starting budesonide strongly supports the diagnosis. Conversely, IBS-D does not respond meaningfully to budesonide because there is no mucosal inflammation to suppress. Some clinicians use a budesonide trial as a diagnostic adjunct in patients with chronic watery diarrhea when biopsy results are equivocal or unavailable. This is not a replacement for histological diagnosis, but the treatment response provides clinically useful information.
Frequently Asked Questions
Can you have both IBS and microscopic colitis?
Yes. Some patients with confirmed microscopic colitis also have visceral hypersensitivity or altered gut-brain signaling that meets IBS criteria. Treating the microscopic colitis with budesonide may resolve diarrhea but leave residual pain or bloating that requires separate IBS-directed management. However, it is important to treat the microscopic colitis first before attributing remaining symptoms to IBS.
Is microscopic colitis a form of inflammatory bowel disease?
Microscopic colitis is classified as a distinct form of inflammatory bowel disease in some gastroenterology frameworks, separate from Crohn's disease and ulcerative colitis. Unlike those conditions, it does not cause visible mucosal damage, does not increase colorectal cancer risk, and responds to different treatments. Its classification varies by institution and guideline.
Can microscopic colitis go away on its own?
Some cases of microscopic colitis resolve spontaneously, particularly drug-induced cases after the offending medication is discontinued. However, many patients have a chronic relapsing course that requires ongoing budesonide therapy. Spontaneous remission rates vary widely in studies, from 15% to over 50%, depending on follow-up duration and patient characteristics.
Does microscopic colitis increase the risk of colon cancer?
Current evidence does not support an increased risk of colorectal cancer in patients with microscopic colitis. This distinguishes it from ulcerative colitis and Crohn's colitis, where prolonged inflammation does increase cancer risk. Patients with microscopic colitis do not require more frequent colonoscopic surveillance than the general population.
What age group is most affected by microscopic colitis?
The median age at diagnosis is approximately 65 years, and incidence is highest in women over 50. However, microscopic colitis can occur at any age, including in adults under 40. Younger patients and men are more likely to be overlooked because clinicians may not consider the diagnosis outside the typical demographic.
â ī¸This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition.